Fractyl Health (GUTS) Income from Continuing Operations (2023 - 2026)
Fractyl Health (GUTS) reported Income from Continuing Operations of 20227000.0 for Q1 2026, up 16.61% year-on-year from 17345805.62 in Q1 2025, and up 10.65% quarter-over-quarter from 22639000.0 in Q4 2025.
Fractyl Health (GUTS) has 4 years of Income from Continuing Operations data on file, last reported at 20227000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 16.61% year-over-year to 20227000.0; the trailing twelve-month figure through Mar 2026 stood at 91247000.0 (up 2.09% YoY), and the FY2025 full-year result was 95276000.0, down 6.59% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 20227000.0, up from 22639000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11690000.0 in Q1 2023 and bottomed at 25853000.0 in Q2 2025.
- A 4-year average of 19574153.85 and a median of 21610000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 95.59% in 2024 and grew 16.61% in 2026, its largest moves.
- Tracing GUTS's Income from Continuing Operations over 4 years: stood at 12518000.0 in 2023, then slumped by 95.59% to 24484000.0 in 2024, then advanced by 7.54% to 22639000.0 in 2025, then rose by 10.65% to 20227000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 20227000.0, 22639000.0, and 22528000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | -20.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.23 Mn |
| Dec 31, 2025 | -22.64 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -25.85 Mn |
| Mar 31, 2025 | -24.26 Mn |
| Dec 31, 2024 | -24.48 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -21.61 Mn |
| Mar 31, 2024 | -20.44 Mn |
| Dec 31, 2023 | -12.52 Mn |
| Sep 30, 2023 | -13.65 Mn |
| Jun 30, 2023 | -11.72 Mn |
| Mar 31, 2023 | -11.69 Mn |